Table 2.
Multivariate Cox proportional hazards regression analysis of the development cohort
| Postoperative Model | Preoperative Model | |||||
|---|---|---|---|---|---|---|
| HR a | 95% CI b | P | HR | 95% CI | P | |
| Age (“≤65”as reference) | 0.004 | 0.000 | ||||
| 66–80 | 1.075 | 0.935–1.236 | 0.311 | 1.285 | 1.123–1.470 | 0.000 |
| >80 | 1.391 | 1.143–1.694 | 0.001 | 1.977 | 1.643–2.378 | 0.000 |
| Sex (“Male” as reference) | ||||||
| Female | 0.961 | 0.843–1.095 | 0.548 | 0.990 | 0.869–1.129 | 0.885 |
| Race (“White” as reference) | 0.600 | 0.593 | ||||
| Black | 0.984 | 0.823–1.177 | 0.863 | 0.962 | 0.805–1.148 | 0.665 |
| Other | 0.923 | 0.789–1.079 | 0.313 | 0.923 | 0.791–1.078 | 0.314 |
| Tumor location (“Cardia” as reference) | 0.008 | 0.020 | ||||
| Non-cardia | 0.816 | 0.684–0.974 | 0.024 | 0.935 | 0.785–1.113 | 0.449 |
| Overlapping lesion | 1.054 | 0.829–1.340 | 0.669 | 1.241 | 0.977–1.577 | 0.077 |
| Stomach, NOSc | 1.014 | 0.784–1.312 | 0.915 | 1.129 | 0.876–1.455 | 0.348 |
| Tumor size (“≤30 mm” as reference) | 0.033 | 0.041 | ||||
| 31-50 mm | 0.985 | 0.802–1.209 | 0.882 | 1.120 | 0.914–1.373 | 0.273 |
| > 50 mm | 0.833 | 0.684–1.014 | 0.069 | 0.938 | 0.773–1.138 | 0.515 |
| Subtype (“Intestinal type” as reference) | 0.536 | 0.267 | ||||
| Diffuse type | 0.861 | 0.664–1.117 | 0.260 | 0.925 | 0.717–1.193 | 0.547 |
| Adenocarcinoma, NOS | 0.997 | 0.846–1.175 | 0.972 | 1.095 | 0.932–1.287 | 0.269 |
| Other adenocarcinoma | 0.906 | 0.708–1.159 | 0.431 | 0.943 | 0.738–1.206 | 0.642 |
| Grade (“Grade1/2” as reference) | ||||||
| Grade3/4 | 1.334 | 1.155–1.540 | 0.000 | 1.269 | 1.100–1.463 | 0.001 |
| T category-AJCCd 7th (“T1” as reference) | 0.000 | 0.000 | ||||
| T2 | 1.395 | 0.894–2.179 | 0.143 | 1.252 | 0.803–1.953 | 0.321 |
| T3 | 1.906 | 1.341–2.708 | 0.000 | 1.658 | 1.171–2.348 | 0.004 |
| T4a | 2.284 | 1.594–3.273 | 0.000 | 1.971 | 1.382–2.811 | 0.000 |
| T4b | 2.457 | 1.704–3.542 | 0.000 | 2.128 | 1.481–3.058 | 0.000 |
| N category-AJCC 7th (“N0” as reference) | 0.000 | |||||
| N1 | 1.341 | 1.082–1.662 | 0.007 | – | – | – |
| N2 | 2.003 | 1.579–2.542 | 0.000 | – | – | – |
| N3 | 2.128 | 1.617–2.801 | 0.000 | – | – | – |
| N+ | – | – | – | 1.397 | 1.137–1.717 | 0.001 |
| Metastatic site(s) (“Distant LN(s)e” as reference) | 0.000 | 0.000 | ||||
| Viscera | 1.496 | 1.255–1.783 | 0.000 | 1.586 | 1.334–1.886 | 0.000 |
| Viscera plus distant LN(s) | 1.810 | 1.389–2.359 | 0.000 | 1.782 | 1.372–2.314 | 0.000 |
| Distant metastasis, NOS | 1.748 | 1.223–2.497 | 0.002 | 1.664 | 1.173–2.362 | 0.004 |
| Gastrectomy (“Partial gastrectomy” as reference) | 0.078 | |||||
| Near-total or total gastrectomy | 0.838 | 0.718–0.978 | 0.025 | – | – | – |
| Gastrectomy, NOS | 0.930 | 0.801–1.080 | 0.343 | – | – | – |
| No. of regional LN(s) examined (“≤10” as reference) | ||||||
| > 10 | 0.684 | 0.591–0.792 | 0.000 | – | – | – |
| Surgery to other site(s) or node(s) (“No” as reference | ||||||
| Yes | 1.008 | 0.877–1.159 | 0.913 | – | – | – |
| Chemotherapy (“No/Unknown” as reference | ||||||
| Yes | 0.514 | 0.448–0.589 | 0.000 | – | – | – |
| Radiotherapy (“No/Unknown” as reference | ||||||
| Yes | 0.778 | 0.647–0.936 | 0.008 | – | – | – |
ahazard ratio; bconfidence interval; cnot otherwise specified; dAmerican Joint Committee on Cancer; elymph node(s)